PROGRAM OVERVIEW

This PhD program in Biology is led by Professor Wei-Guo Zhu, Dean of the Shenzhen University School of Medicine. This cross-disciplinary program will ensure that students are familiar with scientific frontiers in the life sciences, and gain theoretical knowledge, professional experience in biological techniques used in the research laboratory setting and science-based critical thinking. Graduates of this program will have the ability to undertake independent research and work creatively in the field of biomedical science.

Main research fields:

1. Biochemistry and Molecular Biology

Students will study the structure and function of biological macromolecules such as nucleic acids and proteins; explore the biochemical basis and regulatory mechanisms of cell metabolism and homeostasis; and make scientific breakthroughs in the fields of genomic homeostasis, the molecular mechanisms of autophagy, and the pathogenic mechanisms and early diagnosis of major diseases. The mentors in this subprogram have made many breakthroughs in above-mentioned areas and thus are internationally competitive and renowned.

2. Cancer Biology

Students will focus on the biological basis of DNA replication, DNA damage repair, cancer chemoradiotherapy and immunotherapy, and the molecular mechanisms underlying the tumor microenvironment regulating pancreatic cancer metastasis; interpret the molecular mechanisms of maintaining genomic stability; explore new carcinogenic mechanisms and cancer therapeutic targets; and develop new anticancer lead compounds. The mentors in this subprogram are world renowned experts who have  published numerous original research papers in high-profile international journals such as Molecular Cell, Cell Research, and PNAS. In addition, they continuously host an international conference series on DNA repair.

CORE COURSES

Frontiers in Life Science, Academic and Professional English, Biochemistry and Molecular Biology, Advanced Cell Biology and Disease, Cancer Biology

CAREER PROSPECTS

Graduates will be able to follow careers in the biomedical sciences for both academic and industry.

Consultation

Email: [email protected]                  

英文名

SHUNICHI TAKEDA

聯系郵箱

[email protected]

中文簡介

武田教授的實驗室主要研究抗癌藥物的分子機制。我們的研究目標是提供一種可預測不同抗癌療法對不同癌癥患者治療療效的情況，并為每個患者提供最佳的治療。每個患者的癌癥特征都有很大的不同，例如，每個癌基因的活性和抗癌治療的療效在每個乳腺癌患者之間都有很大的不同。在不久的將來，有可能可以確定每個惡性腫瘤病人中許多基因的活性狀態。抗癌藥物會殺死循環中的正常細胞，產生非常嚴重的副作用。因此，在實際治療前預測抗癌藥物的療效和副作用的發生是非常重要的。武田教授的實驗室一直致力于干擾人類癌細胞中的基因研究，并檢測每個基因的活性對抗癌藥物療效的影響。本研究將有助于通過分析惡性腫瘤中基因的活性狀態來預測不同療法的療效。這項研究也讓學生系統地學習基因研究的方法，包括基因破壞和基因破壞細胞的許多表型分析，與大家分享更多基因的突變細胞進行科學研究。

英文簡介

Prof. Takeda’s laboratory has investigated molecular mechanisms underlying anti-cancer drugs. The goal of our study is to develop the method of predicting the efficacy of various anti-cancer therapies on individual cancer patients and to offer the best therapy to each patient. The character of cancers arising in each patient significantly vary, for example, each oncogene’s activity and the efficacy of anti-cancer therapies are very different from one breast cancer patient to another. It is possible in the near future to determine the activity status of many genes in each patient’s malignant tumor. Anti-cancer drugs kill actively cycling normal cells causing very severe side effects. Thus, it is very important to anticipate the efficacy of anti-cancer drugs and the occurrence of side effects before actual treatments. Prof. Takeda’s laboratory has been disrupting genes in human cancer cells and examining the effect of each gene’s activity on the efficacy of anti-cancer drugs. This study will contribute to the prediction of different therapies’ efficacy by analyzing the activity status of genes in malignant tumors. This study also allows students to systematically learn methods of the genetic study, including gene disruption and many phenotypic analyses of gene-disrupted cells, sharing mutant cells of many genes with colleagues.

英文名

XU, Xingzhi

聯系郵箱

[email protected]

中文簡介

深圳大學特聘教授、醫學部副主任，國際先進材料協會（IAAM）會士，《Genome Instability & Disease》常務主編、中國細胞生物學學會細胞信號轉導分會副會長（2015-2023）。長期致力于DNA損傷應答、DNA復制及復制應激、基因組穩定性維持的研究，并開發靶向基因組穩定性的抗癌先導化合物。在國際主流雜志發表SCI論文100余篇；主編《腫瘤生物學導論》（科學出版社，2014）。2011年創建DNA損傷應答北京市重點實驗室并任主任（2011-2017）；2010年創辦并連續主辦DNA損傷應答與人類疾病國際研討會（isDDRHD）年會系列并成為有國際影響力的品牌會議，是中國DNA修復領域的核心召集人。

英文簡介

Distinguished Professor of Shenzhen University, Vice Dean of School of Medicine, Fellow of the International Association for Advanced Materials (IAAM), Deputy Editor-in-chief of Genome Instability & Disease, Vice President of Chinese Society for Cell Signal Transduction, CSCB (2015-2023). He has long been devoted to the research of DNA damage response, DNA replication and replication stress response, and maintenance of genome stability, and has developed anticancer lead compounds targeting genome homeostasis. He has published more than 100 SCI papers in international mainstream journals; edited "Principles of Cancer Biology" (Science Press, 2014). In 2011, he founded the Beijing Key Laboratory of DNA Damage Response and served as the director (2011-2017); in 2010, he founded and successively hosted the annual conference series of the international symposium on DNA Damage Response and Human Diseases (isDDRHD), which has become an internationally influential brand conference. Therefore, he becomes the core convener in the field of DNA repair in China.

英文名

Wei-Guo Zhu

聯系郵箱

[email protected]

中文簡介

朱教授是深圳大學醫學部特聘教授，博士生導師，醫學部主任，多項科技部“973”及“863”計劃負責人; 國家基金委創新團隊負責人;國家基金委重大及重點項目負責人; 國家杰出青年基金獲得者。

朱教授聚焦探討組蛋白修飾酶和相關的組蛋白修飾在DNA損傷應答、細胞自噬及基因調控等過程中的功能及其在腫瘤發生發展中的作用，發現了一系列重要的腫瘤治療新靶點和新方法，為腫瘤的精準治療提供了重要的理論基礎和實驗支撐。他在國際主流期刊發表160余篇研究論文，包括Nature, Nature Cell Biology, Molecular Cell, PNAS等，被引用15000余次。學術研究主要包括以下三個方面：

1.識別一系列參與腫瘤細胞DNA損傷反應的組蛋白修飾位點/組蛋白修飾酶，為腫瘤放療和化療提供理論依據；

2. 揭示組蛋白修飾酶在自噬多層次調控中的生物學功能；

3.鞏固了蛋白質乙酰化修飾參與腫瘤表觀遺傳治療的理論基礎。

英文簡介

Prof. Zhu is a distinguished Professor of Shenzhen University,  and Dean of the School of Medicine, Shenzhen University, Ph.D Supervisor. He is the head of a number of "973" and "863" programs of the Ministry of Science and Technology of China,  head of the National Funding Commission’s innovation team of NSFC, head of the National Funding Commission’s key R&D program, Recipient of the National Outstanding Distinguished Youth Scientist，as well as the head of major and key projects of the National Foundation Commission of China.

Prof. Zhu focuses on the function of the histone modification enzymes and histone modification in the DNA damage response, autophagy and gene regulation, and its role in cancer development. He found a series of important new targets and methods for cancer treatment, which provides an important theoretical basis and experimental support for the accuracy of tumor therapy. He has published more than 160 research papers in leading international journals including Nature, Nature Cell Biology, Molecular Cell, and PNAS which earned more than 15,000 citations. His academic research mainly includes the following three aspects:

1. Identifying a series of histone modifications sites / histone modifying enzymes that participate in the DNA damage response of tumor cells, providing a theoretical basis for tumor radiotherapy and chemotherapy.

2. Revealing the biological functions of histone-modifying enzymes in the multi-level regulation of autophagy.

Consolidating the theoretical basis for the involvement of protein acetylation modification in tumor epigenetic therapy.

英文名

Huiqiang Lou

聯系郵箱

l[email protected]

中文簡介

樓慧強實驗室致力于探討腫瘤發生的兩種假說：基因組不穩定性和代謝紊亂，尤其是兩個假說之間的關聯。我們綜合運用遺傳學、生物化學、細胞生物學及系統生物學等手段，一方面研究DNA復制及其關聯事件出錯的原因；另一方面研究營養（糖）代謝如何影響DNA復制與基因組穩定性。近五年代表作發表在Genes & Dev, EMBOJ, Cell Rep, EMBO Rep, CMLS, PLoS Genet 等高水平雜志。

英文簡介

The Lou Group is devoted to uncover the potential crosstalk between metabolic dysregulation and genome instability, the two major resources which are considered to underlie cancer initiation. We apply multidisciplinary approaches such as genetics, biochemistry, cell biology, quantitative biology and synthetic biology to investigate DNA replication, co-replication events and whether/how sugar metabolism affects DNA replication/genome integrity. Our recent high-impact publications include Genes & Dev, EMBOJ, Cell Rep, EMBO Rep, CMLS, PLoS Genet.  

英文名

Cheng Yong-Xian

聯系郵箱

[email protected]

中文簡介

程永現教授長期從事中藥藥效物質研究，創建了中醫治則治法指導下闡明中藥藥效物質的新模式，形成了圍繞慢性疾病運用“衷中參西”方法揭示中藥藥效物質的新體系，并在樹脂、靈芝、昆蟲三大特色中藥研究方面取得突破性進展。其研究工作涉及中藥化學成分分離、鑒定、活性發現及采用化學生物學方法鑒定靶標。主持（過）NSFC-云南聯合基金重點項目、國家自然科學基金重點項目、十二五國家重大新藥創制專項課題、十三五國家重點研發計劃課題等。曾先后獲云南省自然科學一等獎、廣東省科技進步一等獎、中華醫學科技一等獎、國家科技進步二等獎等。已發表論文300余篇、獲授權專利50余件，培養碩士和博士研究生100余名。

英文簡介

My research interests are on the isolation, structural characterization, biological evaluation, structural optimization, and mechanistic exploration of natural products produced by insects, Ganoderma fungi, and plant resins. Moreover, our research deals with target identification of bioactive small molecules using chemical biology approaches. I have focused on compounds with potential reno-protective and neuro-protective effects inspired by traditional Chinese medicine philosophy or bionic concepts. In particular, I made great progress on nonpeptide small molecules from the insects and aromatic meroterpenoids from Ganoderma fungi, which represents pioneering work in this field. Given these achievements, I was supported by the National Science Fund for Distinguished Young Scholars in China. My future research will utilize biotic and abiotic stressors, such as light induction, to create chemical and biological diversities of metabolites from the above materials. Under the support of projects such as National Major Scientific and Technological Special Project for “Significant New Drugs Development” during the Eleventh and Twelfth Five-year Plan Periods, NSFC-Joint Foundation of Yunnan Province, National Natural Science Foundation of China, Knowledge Innovation Project of the Chinese Academy of Sciences, and West Light Foundation of the Chinese Academy of Sciences, I have published 300 papers (e.g. JASN, Org Lett, J Nat Prod) and applied for 50 patents. I am currently mentoring two PhD candidates and 20 MSc candidates.

英文名

Desheng Lu

聯系郵箱

d[email protected]

中文簡介

呂德生教授是深圳大學醫學部特聘教授，深圳大學醫學部藥理學系主任，深圳市孔雀計劃B類人才。他的主要研究方向為腫瘤干細胞相關信號通路（包括Wnt信號通路）、腫瘤干細胞和抗腫瘤新藥的研發。1998年，獲得加拿大多倫多大學博士學位，迄今已發表60多篇科學論文，論文已被引用超過3400次，H-指數為27，目前擔任PNAS、 Blood、 Cancer Research、Clinical Cancer Research等國際著名雜志特約審稿專家，現任深圳市分析測試協會醫學測試專委會副主任委員。

英文簡介

Prof. Lu is a distinguish professor and Chairman of Department of Pharmacology in Shenzhen University Health Science Center. He won the Shenzhen Peacock Talent Award (Class B). His main research interests are cancer stem cells-associated signaling transduction (especially Wnt signaling pathway), cancer stem cells and anti-cancer drug discovery. He received his doctorate in medical genetics from University of Toronto in 1998. So far, he has published more than 60 scientific papers, including many high-level articles published in some prestigious international journals. These papers have been cited more than 3400 times with an H-index of 27. He has served as a reviewer of internationally renowned journal such as PNAS, Blood, Cancer Research, and Clinical Cancer Research. He is currently the deputy chairman of the Medical Testing Committee of Shenzhen Analytical Testing Association.

英文名

Aifa Tang

聯系郵箱

[email protected]

中文簡介

  從事腫瘤基因組基礎與重大疾病體外診斷研究。參與發起“中國泌尿生殖系統腫瘤基因組計劃”和“國際泌尿生殖系統腫瘤基因組計劃”，現為國際腫瘤基因組協作組（ICGC）膀胱癌項目首席研究員（PI）和腎癌項目首席研究員（PI）。以第一作者身份在Nature Genetics封面文章發表中國第一篇實體瘤的腫瘤基因組研究論文，該文科學發現提示了腫瘤發生的“染色質重塑-腫瘤抑制”新理論，目前該文已被引用338次。第二篇Nature Genetics研究論文，其科學發現提示了腎癌發生的低氧誘導理論，目前已被引用144次。通過腎癌單細胞測序，首次建立了腫瘤單細胞測序技術體系，該研究為解釋腎癌放化療不敏感提供了直接的理論證據，該研究在Cell雜志發表，目前已被引用291次。源頭發現一批與腫瘤復發及預后相關的新腫瘤基因突變；開發ctDNA膀胱癌靶向深度測序檢測新方法；已完成腫瘤熱點基因突變臨床服務分析165例。

英文簡介

Engaged in research on tumor genome foundation and in vitro diagnosis of major diseases. He participated in the launching of the "China Urogenital Cancer Genome Project" and the "International Urogenital Cancer Genome Project", and is now the chief researcher (PI) of the International Cancer Genome Cooperation Group (ICGC) bladder cancer project and the chief researcher (PI) of the kidney cancer project. As the first author, He published the first tumor genome research paper on solid tumors in China on the cover article of Nature Genetics. The scientific findings of this paper suggest a new theory of "chromatin remodeling tumor inhibition" in tumor development. Currently, this article has been cited 338 times. The second Nature Genetics research paper, whose scientific findings suggest the theory of hypoxia induction in renal cell carcinoma, has been cited 144 times so far. A tumor single cell sequencing technology system has been established for the first time through single cell sequencing of renal cancer. This study provides direct theoretical evidence for explaining the insensitivity of renal cancer to radiotherapy and chemotherapy. The study was published in Cell magazine and has been cited 291 times so far. Discovering a batch of new tumor gene mutations related to tumor recurrence and prognosis at the source; To develop a new method of ctDNA targeting depth sequencing for bladder cancer; A clinical service analysis of 165 cases of tumor hotspot gene mutations has been completed.

英文名

Liyun Gong

聯系郵箱

[email protected]

中文簡介

  鞏麗云，女，教授，醫學博士,留學博士研究生導師，深圳市生物化學與分子生物學會理事，廣東省醫學教育協會生物化學與分子生物學專業委員會委員，美國國立衛生研究院（NIH）美國國立癌癥研究所（NCI）Guest Researcher。主持和參與多項國家自然科學基金、廣東省自然科學基金和深圳市自由探索等研究項目，在Clinical Cancer Research，Journal of Pathology，Cell Death&Disease、Oncogene等權威TOP期刊發表研究論文多篇。目前從事絲精氨酸蛋白激酶1（SRPK1）在非小細胞肺癌靶向藥物EGFR-TKI耐藥的機制研究。

學習經歷

2005年9月---2008年7月  中山大學 中山醫學院 微生物學博士

2000年9月---2003年7月  大連醫科大學 免疫學碩士

1992年9月---1997年7月  大連醫科大學 醫學學士

英文簡介

Liyun Gong, Doctor of Medicine, supervisor of doctoral students abroad, director of the Shenzhen Society of Biochemistry and Molecular Biology, member of the Biochemistry and Molecular Biology Professional Committee of the Guangdong Medical Education Association, and Guest Researcher of the National Cancer Institute (NCI) at the National Institutes of Health (NIH) in the United States. Led and participated in multiple research projects such as the National Natural Science Foundation of China, Guangdong Provincial Natural Science Foundation, and Shenzhen Free Exploration, and published multiple research papers in authoritative TOP journals such as Clinical Cancer Research, Journal of Pathology, Cell Death&Release, and Oncogene. Currently engaged in research on the mechanism of resistance of serine arginine protein kinase 1 (SRPK1) to the targeted drug EGFR-TKI in non-small cell lung cancer.

Education

? BMed(1997), Medical Laboratory, Dalian Medical University  

? MMed(2003), Immunology, Dalian Medical University

? DMed(2008), Zhongshan Medical school, Sun Yat-sen University

Research interests: Tumor metastasis, non-small cell lung cancer, kinase target drug resistance. Our study focuses on the mechanism of serine arginine protein kinase (SRPK1) promoting molecular targeted drug EGFR-TKIs resistance in non-small cell lung cancer (NSCLC). We found that the non-kinase domain of SRPK1 may play a key role in tumorigenesis indicating that SRPK1 may be a potential drug target.

英文名

Su Wen

聯系郵箱

c[email protected]

中文簡介

  蘇文，深圳大學副教授、特聘研究員，深圳市孔雀人才C類人才，研究方向為脂滴在高血壓、脂肪肝、糖尿病等代謝性疾病發病過程中的調控機制，非酒精性脂肪性肝炎（NASH）新藥研發。北京大學優秀畢業生，獲國家博士后基金一等資助，國家自然科學基金青年基金、面上基金，深圳市基礎項目等科研基金的資助。在國際上首次建立了正常人肝臟和脂肪臟的脂滴蛋白數據庫，發現新型的脂滴相關蛋白HSD17B13參與人非酒精性脂肪肝和脂肪性肝炎的發生，為NASH的診斷和藥物研發提供了新的靶點。在Nature commun、PNAS、Biochim Biophys Acta Mol Basis Dis、Am J Physiol Endocrinol Metab等雜志發表研究論文，Am J Physiol Endocrinol Metab.審稿人，美國糖尿病協會會員，中國生理協會青年委員、生理學報青年編委。

英文簡介

Dr. Wen Su is an associate professor at the department of pathophysiology, Shenzhen University Health Science Center. She received her PH.D. degree at Peking University, China in 2014. Her research field include lipid metabolism, lipid droplet proteins, mechanisms of lipid dysregulation in metabolic diseases such as NAFLD/NASH, obesity and diabetes, Her original research about 17β-HSD13 provides a potential link between LD proteins and NAFLD. Her discovery about 17β-HSD13 was confirmed in several large-scale population GWAS studies which reveals that an insertion SNP72613567 of HSD17B13 gene represents a loss-of-function and confer a strong protective effect on liver injury, inflammation, fibrosis, cirrhosis, She has published a serious articles as the first author or corresponding author, including Nature commun，PNAS、Biochim Biophys Acta Mol Basis Dis、Am J Physiol Endocrinol Metab. et al. She is a member of Chinese Physiology Association and American Diabetes Association.

英文名

Yin Peng

聯系郵箱

y[email protected]

中文簡介

  2010年畢業于Loyola University Chicago獲生物醫學博士學位。現任深圳大學醫學部病理學系副教授。主要研究方向是胃腸道腫瘤中的非編碼RNA作用機制及其相關信號通路，發表SCI一作和通訊作者論文20篇，包括 Oncogene，Molecular Cancer，Cancer Letters等。主持國家自然科學基金2項、廣東省自然科學基金2項及廣東省醫學科學基金，深圳市基礎研究，深圳高層次人才基金，深圳大學啟動基金等多個項目，總經費超過500萬。美國腫瘤學會AACR會員。深圳市孔雀C類人才。

英文簡介

Dr. Yin Peng received the PhD degree in Molecular and Cellular Biochemistry from Loyola University Chicago in 2010. She is currently an associate professor in Department of Pathology at Shenzhen University, China. Her long-standing research interests lie in elucidating the molecular mechanisms of cell signaling transduction pathway underlying tumorigenesis. Her lab is actively exploring how oncogenic circRNAs regulate critical signaling transduction pathways, such as the Wnt/β -catenin pathway and NF-κB signaling pathway to promote cell survival, proliferation and migration in cancer cells. She has published over 20 first author/corresponding author papers in professional, peer-reviewed journals including Oncogene, Molecular Cancer, Cancer Letters. She is an AACR member and Shenzhen Peacock Talent C.

英文名

Bin Peng

聯系郵箱

b[email protected]

中文簡介

彭斌，博士，深圳大學副教授，留學博士生導師/碩士生導師。致力于基因組不穩定性與人類疾病（如腫瘤、先天性小頭畸形）方面的研究，側重于翻譯后修飾如磷酸化、泛素化協調調控DNA損傷/DNA復制脅迫應答分子機制的闡明。此外，在篩選小分子抑制劑、優化抗癌先導物和評估其生物學效應方面積攢了一定經驗，在國際主流雜志Proc Natl Acad Sci U S A, Nucleic Acids Res, eLife, iScience, J Biol Chem, J Med Chem和Eur J Med Chem等發表SCI 論文21篇。主持科技部國家重點研發計劃子課題、國家自然科學基金面上項目和青年項目、廣東省自然科學基金項目和深圳市科技計劃基礎研究項目等多個科研項目。參與國家自然科學基金重大項目、重點項目及國際合作等。

英文簡介

Peng Bin, Ph.D., associate professor at Shenzhen University, supervisor of Ph.D students/master students. Committed to research on genome instability and human diseases (such as tumors, congenital microcephaly), focusing on the elucidation of the molecular mechanisms of post-translational modifications such as phosphorylation and ubiquitination to coordinately DNA damage/DNA replication stress response. In addition, he has accumulated certain experience in screening small molecule inhibitors, optimizing anti-cancer leads and evaluating their biological effects. He has published 21 SCI papers in journal such as Proc Natl Acad Sci U S A, Nucleic Acids Res, eLife, iScience, J Biol Chem, J Med Chem and Eur J Med Chem, etc. He has presided over a number of scientific research projects such as sub-topics of the Ministry of Science and Technology’s National Key R&D Plan, National Natural Science Foundation General Projects and Youth Projects, Guangdong Provincial Natural Science Foundation Projects, and Shenzhen Science and Technology Plan Basic Research Projects.

英文名

Xue Liu

聯系郵箱

x[email protected]

中文簡介

  劉雪, 深圳大學醫學部副教授，深圳市海外高層次人才，廣東省特支計劃青年拔尖人才獲得者。2021年8月入職深圳大學醫學部，組建人類病原性細菌研究團隊（http://xliugroup.com/）。近年發表SCI論文20余篇，其中第一作者（含共同一作）論文10篇，包括Cell Host & Microbe, Molecular Cell, Nature Protocols, Molecular Systems Biology (封面文章）等國際知名高水平期刊。首次鑒定了LafB可為廣譜的鏈球菌菌的疫苗靶點，并獲國際專利1項。

“克菌治病”課題組目前研究方向包括以下三個方面：

1）重要人類病原細菌的致病機理。

2）腸道非模式細菌的高效遺傳篩選平臺開發。

  3) 采用時空組學探究細菌感染關鍵病灶的發病機制。

英文簡介

Liu Xue is an associate professor at the Medical School of Shenzhen University, a high-level overseas talent in Shenzhen, and a recipient of the Guangdong Province Special Support Program for Young Talents. In August 2021, she joined the Medical School of Shenzhen University and established the Human Pathogenic Bacteria Research Team (http://xliugroup.com/). In recent years, she has published more than 20 SCI papers, including 9 as the first author or co-first author, in internationally renowned high-level journals such as Cell Host & Microbe, Molecular Cell, Nature Protocols, and Molecular Systems Biology (cover article). She identified LafB as a target for pneumococcal vaccine develop with wide-range protection against strains with different serotypes.

Our "Fighting Bacterial Diseases" research group is currently focused on three main areas:

1) The pathogenic mechanisms of important bacterial human pathogens.

2) The development of efficient genetic screening platforms for non-model bacteria in the gut.

3) Using spatial and temporal omics to explore the pathogenesis of key lesions in bacterial infections.

英文名

Xingsheng Shu

聯系郵箱

[email protected]

中文簡介

    舒興盛，博士，副教授，深圳市海外高層次人才（C類）。2008年于北京大學生命科學學院獲學士學位，2012年于香港中文大學醫學院臨床腫瘤學系獲博士學位，現任深圳大學醫學部基礎醫學院副教授。舒興盛博士長期致力于腫瘤中的表觀遺傳調控異常的機制及相關的轉化治療研究，目前共發表SCI論文三十余篇，被引用1300余次，H-index為20，其中近5年在PNAS、Oncogene、Journal of Pathology、Theranostics等高水平學術期刊以通訊或第一作者發表論文十余篇，獲得中國發明專利授權兩項，并主持完成多項國家和省市級項目，目前有包括國自然面上項目在內的多個項目在研。更多研究情況請參看鏈接：https://www.ncbi.nlm.nih.gov/myncbi/xingsheng.shu.1/bibliography/public/。

英文簡介

    Dr. Xing-sheng Shu received his B.S. degree from the School of Life Sciences, Peking University in 2008 and his Ph.D. degree from the Department of Clinical Oncology, The Chinese University of Hong Kong in 2012. He is currently an Associate Professor at the School of Medicine, Shenzhen University. Dr. Shu has been working on abnormal epigenetic and transcriptional regulation in cancer and related translational research for cancer therapy. He has published more than 30 SCI papers with more than 1300 citations and an H-index of 20, including more than 10 papers in PNAS, Oncogene, Journal of Pathology, Theranostics and other high impact journals in recent 5 years as corresponding or first author. He also holds two invention patents, and completed many national and provincial research projects. For more information about his research, please refer to the link: https://www.ncbi.nlm.nih.gov/myncbi/xingsheng.shu.1/bibliography/public/.